announced today the commercial release of the Belos DR-T, the world's first dual-chamber, rate responsive implantable cardioverter defibrillator (ICD) that is able to instantly and automatically notify a physician when a patient has received life-saving therapy -- without any involvement from the patient.
The Belos dual-chamber family received market approval from the Food and Drug Administration (FDA) on December 20, 2002.
Belos dual-chamber ICDs use SMART Detection(TM) and Redetection(TM), the most accurate and reliable AV discrimination features available to distinguish life-threatening arrhythmias from normal heart rhythms.
Food and Drug Administration (FDA) has approved the commercial release of the Belos VR-T Implantable Cardioverter Defibrillator (ICD) with Home Monitoring technology.
With the exclusive Home Monitoring System, the Belos VR-T ICD is able to automatically transmit critical data about the patient's current condition to the physician's office, anytime, anywhere.
Like other members of the BIOTRONIK ICD family, Belos VR-T has a full feature set, including tiered therapy and a sophisticated tachyarrhythmia diagnostic package.
implantation of Belos VR-T, the world's only state-of-the-art ICD featuring the company's exclusive Home Monitoring Technology.
The extremely compact (39cc/12mm) Belos VR-T ICD is a full-featured device with tiered therapy and a sophisticated tachyarrhythmia diagnostic package.
The Belos VR-T is equipped with a transmitter that automatically sends diagnostic data to the attending physician via the BIOTRONIK Home Monitoring System.
The patient received the Belos VR-T to treat his arrhythmias and prevent sudden cardiac death.
Food and Drug Administration (FDA) approval of the Belos VR implantable cardioverter defibrillator (ICD).
The approval represents a significant milestone for the company, as Belos VR completes BIOTRONIK's line of downsized rate-adaptive ICDs.